MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation

International Journal of Oncology
Junwoo LeeSeunghee Bae

Abstract

Chemoresistance is one of most critical clinical problems encountered when treating patients with ovarian cancer, due to the fact that the disease is usually diagnosed at advanced stages. Metformin is used as a first‑line drug for the treatment of type 2 diabetes; however, drug repositioning studies have revealed its antitumor effects, mainly mediated through AMP‑activated protein kinase (AMPK) activation and AKT/mammalian target of rapamycin (mTOR) pathway inhibition in various types of cancer, including drug‑resistant cancer cells. The current study revealed that the novel antitumor mechanism of metformin is mediated by regulation of mitochondrial E3 ubiquitin protein ligase 1 (MUL1) expression that negatively regulates AKT. The results demonstrated that metformin decreased the expression of AKT protein levels via MUL1 E3 ligase. In addition, metformin increased both mRNA and protein levels of MUL1 and promoted degradation of AKT in a proteasome‑dependent manner. Silencing MUL1 expression suppressed the metformin‑mediated AKT degradation and its downstream effects. Cell cycle analysis and a clonogenic assay demonstrated that knockdown of MUL1 significantly diminished the antitumor effects of metformin. Together, these data in...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 4, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J EngelD Hölzel
Jul 2, 2003·Nature Reviews. Cancer·Roshan Agarwal, Stan B Kaye
Mar 17, 2004·Cancer Treatment Reviews·Juan Angel Fresno VaraManuel González-Barón
Feb 24, 2005·Seminars in Oncology·Franco M Muggia
Apr 4, 2007·Annals of the New York Academy of Sciences·Su-Hyeong KimYong-Sang Song
May 10, 2008·The Biochemical Journal·Jingxiang Huang, Brendan D Manning
Oct 31, 2009·Journal of Cellular and Molecular Medicine·R RattanV Shridhar
Jan 12, 2010·Developmental Cell·Futoshi SuizuMasayuki Noguchi
Feb 6, 2010·Breast Cancer Research and Treatment·Mahvash ZakikhaniMichael N Pollak
May 7, 2010·Cell Metabolism·Adem KalenderGeorge Thomas
Jun 5, 2010·Critical Reviews in Biochemistry and Molecular Biology·Benoit ViolletFabrizio Andreelli
Apr 28, 2011·CA: a Cancer Journal for Clinicians·Danijela Jelovac, Deborah K Armstrong
Jan 10, 2012·Molecular Cancer Therapeutics·Kiyohito KatoTsutomu Masaki
Feb 23, 2012·Journal of Molecular Endocrinology·Ryan J O DowlingPamela J Goodwin
Mar 14, 2012·Cell Research·Seunghee BaeSungkwan An
Jan 10, 2013·Current Cancer Drug Targets·Mitchell Cheung, Joseph R Testa
Feb 16, 2013·Current Medicinal Chemistry·Giuliana CassinelliPaola Perego
Jan 28, 2014·PloS One·Pratima Nangia-MakkerAdhip P N Majumdar
May 14, 2014·BioMed Research International·Kouji BannoDaisuke Aoki
May 21, 2014·ELife·William W WheatonNavdeep S Chandel
Feb 25, 2015·International Journal of Oncology·Shintaro FujiharaTsutomu Masaki
Mar 18, 2015·Experimental and Therapeutic Medicine·Yingshan LiuWeiyuan Ma
Jan 19, 2016·Diabetologia·Laura J McCreightEwan R Pearson
Aug 16, 2016·SpringerPlus·Gonzalo H Giornelli
Nov 30, 2016·Cancer Metastasis Reviews·Angel Guerrero-ZotanoCarlos L Arteaga
Mar 28, 2017·Current Opinion in Cell Biology·Evan C LienAlex Toker
Apr 26, 2017·International Journal of Oncology·Eri BannoKazuto Nishio
Apr 9, 2018·Pharmacological Reports : PR·Isabella Dos Santos GuimarãesLeticia Batista Azevedo Rangel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Cycle Control & Proteolysis

Key regulators of cell cycle, including cyclins, cyclin dependent kinase inhibitors, DNA replication factors, are controlled by proteolysis. Discover the latest research on cell cycle control and proteolysis.